Immuneering Corp Cl A (IMRX) Stock Price, Quote & News

Company Profile

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inh...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 500 8080

Website: immuneering.com

Address:

245 Main Street, Second Floor, Cambridge, United States

putsandcalls Apr. 2 at 7:13 PM

$IMRX can this pos ever hold a gain?

1 · Reply

watchaddict Apr. 1 at 7:56 PM

$IMRX LFG

0 · Reply

watchaddict Apr. 1 at 12:58 PM

$IMRX 1000 more

0 · Reply

UtahMike Mar. 31 at 4:44 PM

$IMRX Damn…almost sold yesterday. Sometimes what you don’t do is just as important.

2 · Reply

watchaddict Mar. 31 at 12:27 PM

$IMRX 1000 more

0 · Reply

BinaryLogic Mar. 29 at 11:42 PM

$IMRX The Company has $173M in Cash/ST (plus $44M in advances) against $13.5M Total Liabilities and a Cash runway to 2029 as they move into Phs-III study on their lead (pancreatic cancer) drug candidate. Multiplier upside from this level, though as I have stated the macro-economic backdrop is weakening. This stock was trading at/around $1.2 when I first highlighted the Company. Keep that line in mind should equities fall completely out of favor. Multiplier upside on this Company and its stock if/where they convert on Phs-III (IMO). https://www.stocktitan.net/news/IMRX/immuneering-reports-fourth-quarter-and-full-year-2025-financial-gx3c56uf9pt2.html

0 · Reply

dcrown Mar. 27 at 10:32 PM

$IMRX expecting Sanofi news as soon as next week

3 · Reply

watchaddict Mar. 26 at 1:39 PM

$IMRX 1000

0 · Reply

longDstyle Mar. 25 at 1:34 PM

$IMRX added more . $8+ soon

0 · Reply

watchaddict Mar. 25 at 1:09 PM

$IMRX Adding

0 · Reply

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

Mar 6, 2026, 7:45 AM EST - 4 weeks ago

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 2, 2026, 4:05 PM EST - 4 weeks ago

Immuneering to Present at the Leerink Global Healthcare Conference

Feb 18, 2026, 4:05 PM EST - 6 weeks ago

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Jan 8, 2026, 5:45 PM EST - 3 months ago

Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data

Jan 8, 2026, 9:28 AM EST - 3 months ago

Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower

Jan 7, 2026, 6:47 PM EST - 3 months ago

Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript

Jan 7, 2026, 4:00 PM EST - 3 months ago

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Dec 23, 2025, 8:00 AM EST - 3 months ago

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

Dec 17, 2025, 4:05 PM EST - 3 months ago

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

Dec 16, 2025, 8:00 AM EST - 3 months ago

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Nov 25, 2025, 8:00 AM EST - 4 months ago

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 12, 2025, 9:11 PM EST - 5 months ago

Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:05 PM EST - 5 months ago

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

Nov 4, 2025, 4:05 PM EST - 5 months ago

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

Sep 29, 2025, 4:37 PM EDT - 6 months ago

Immuneering Corporation - Special Call

Sep 26, 2025, 4:01 PM EDT - 6 months ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Sep 25, 2025, 2:19 PM EDT - 6 months ago

Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst

Sep 25, 2025, 12:08 AM EDT - 6 months ago

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Sep 24, 2025, 4:05 PM EDT - 6 months ago

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Sep 24, 2025, 4:01 PM EDT - 6 months ago

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Sep 16, 2025, 7:00 AM EDT - 7 months ago

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Sep 10, 2025, 7:00 AM EDT - 7 months ago

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Aug 26, 2025, 4:05 PM EDT - 7 months ago

Immuneering Announces Closing of $25 Million Private Placement

Aug 25, 2025, 8:00 AM EDT - 7 months ago

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

LLY

Aug 21, 2025, 8:00 AM EDT - 8 months ago

Immuneering Announces $25 Million Private Placement

Aug 13, 2025, 4:05 PM EDT - 8 months ago

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 9, 2025, 8:00 AM EDT - 9 months ago

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Jun 17, 2025, 6:00 AM EDT - 10 months ago

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Jun 16, 2025, 8:00 AM EDT - 10 months ago

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

May 29, 2025, 8:00 AM EDT - 11 months ago

Immuneering to Present at the Jefferies Global Healthcare Conference

May 5, 2025, 4:05 PM EDT - 11 months ago

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 21, 2025, 4:30 PM EDT - 1 year ago

Immuneering Corporation Announces Grant of Inducement Award

Mar 20, 2025, 4:05 PM EDT - 1 year ago

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Feb 3, 2025, 4:05 PM EST - 1 year ago

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 7, 2025, 9:28 AM EST - 1 year ago

Why Is Immuneering Stock Trading Higher On Tuesday?

Dec 19, 2024, 8:00 AM EST - 1 year ago

Immuneering Launches Pancreatic Cancer Advisory Board

Dec 13, 2024, 2:10 PM EST - 1 year ago

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

FOLD

Dec 12, 2024, 8:00 AM EST - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Nov 27, 2024, 8:00 AM EST - 1 year ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

May 7, 2024, 4:05 PM EDT - 2 years ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 4:30 PM EDT - 2 years ago

Immuneering Recognizes Melanoma Awareness Month

Apr 9, 2024, 12:00 PM EDT - 2 years ago

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Apr 3, 2024, 4:05 PM EDT - 2 years ago

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

putsandcalls Apr. 2 at 7:13 PM

$IMRX can this pos ever hold a gain?

1 · Reply

watchaddict Apr. 1 at 7:56 PM

$IMRX LFG

0 · Reply

watchaddict Apr. 1 at 12:58 PM

$IMRX 1000 more

0 · Reply

UtahMike Mar. 31 at 4:44 PM

$IMRX Damn…almost sold yesterday. Sometimes what you don’t do is just as important.

2 · Reply

watchaddict Mar. 31 at 12:27 PM

$IMRX 1000 more

0 · Reply

BinaryLogic Mar. 29 at 11:42 PM

0 · Reply

dcrown Mar. 27 at 10:32 PM

$IMRX expecting Sanofi news as soon as next week

3 · Reply

watchaddict Mar. 26 at 1:39 PM

$IMRX 1000

0 · Reply

longDstyle Mar. 25 at 1:34 PM

$IMRX added more . $8+ soon

0 · Reply

watchaddict Mar. 25 at 1:09 PM

$IMRX Adding

0 · Reply

rekc Mar. 24 at 8:06 PM

$IMRX In retrospect, it was a pretty easy trade for the shorts. You knew IMRX was going to come out of the BIO index because of market cap. rules, so you shorted the stock and covered with the index selling.

0 · Reply

watchaddict Mar. 24 at 12:36 PM

$IMRX loading

0 · Reply

AlwaysBullish99 Mar. 24 at 12:49 AM

$IMRX Still need some surprise data

0 · Reply

longDstyle Mar. 23 at 10:54 PM

$IMRX added more today

0 · Reply

bioland Mar. 23 at 7:43 PM

$IMRX Looks like we'll be waiting a month for news...

0 · Reply

D541 Mar. 23 at 5:06 PM

$IMRX 60k$ in

0 · Reply

_JAKE Mar. 23 at 3:28 PM

$IMRX Get them cheap while you can

1 · Reply

watchaddict Mar. 23 at 2:10 PM

$IMRX 1000

0 · Reply

rekc Mar. 23 at 1:54 PM

$IMRX That's definitely the reason.

0 · Reply

hk1914 Mar. 23 at 10:46 AM

$IMRX possible explanation for volume spike on friday, any thought? https://www.marketscreener.com/news/immuneering-corporation-nasdaqgm-imrx-dropped-from-s-p-biotechnology-select-industry-index-ce7e5edcda88f623

1 · Reply

MASTER_CHIEF__117 Mar. 23 at 8:35 AM

$GRWG $OPEN $IMRX $IREN All 4 should should signal reversal today - Especially $GRWG read latest fins - https://www.youtube.com/shorts/wlQa_CzUXrs

0 · Reply

_JAKE Mar. 22 at 5:05 PM

$IMRX

0 · Reply

Market Cap	352.36M
Revenue (ttm)	0.00
Net Income (ttm)	-56.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	597,400
Avg Vol	1,004,186
Day's Range	N/A - N/A
Shares Out	64.65M
Stochastic %K	82%
Beta	0.43
Analysts	Strong Sell
Price Target	$17.00